Patient adherence to fully reimbursed proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) treatment.
Cardiovascular risk
Lipid-lowering therapy
Low-density lipoprotein
Monoclonal antibodies
Secondary prevention
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
14
11
2022
accepted:
12
01
2023
medline:
14
7
2023
pubmed:
23
2
2023
entrez:
22
2
2023
Statut:
ppublish
Résumé
Proprotein convertase subtilisin/kexin-type 9 inhibitor (PCSK9i) treatment reduces cardiovascular events when taken over a long time for secondary prevention. Data on treatment adherence are scarce and maybe affected by co-payment of patients. The aim of this study was to elucidate PCSK9i treatment adherence in a setting of full cost coverage as it is the case in a number of European countries. Baseline data and prescription patterns of all 7302 patients with PCSK9i prescriptions dispensed on the account of Austrian Social Insurances between September 2015 and December 2020 were retrieved and analyzed. A gap of ≥ 60 days between prescriptions was defined as treatment discontinuation. Patient adherence was evaluated as the proportion of days covered (PDC) over the observation period and treatment discontinuation rates were investigated by the Kaplan-Meier method. The mean PDC was 81.8% and was significantly lower in female patients. A PDC of ≥ 80% indicating adequate adherence was found in 73.8%. Of the study population 27.4% discontinued PCSK9i treatment and 49.2% thereof re-initiated treatment during the observation period. Most of the patients who discontinued treatment did so within the first year. Male patients and patients under 64 years showed significantly lower discontinuation and higher re-initiation rates. Considering the high PDC and low discontinuation rates, the majority of patients adhere to PCSK9i treatment. Hence, in a system where PCSK9i treatment is made available at virtually no costs for patients this highly effective treatment is well-accepted as a long-term treatment.
Identifiants
pubmed: 36808306
doi: 10.1007/s00508-023-02154-y
pii: 10.1007/s00508-023-02154-y
doi:
Substances chimiques
PCSK9 Inhibitors
0
Cholesterol, LDL
0
Subtilisins
EC 3.4.21.-
Proprotein Convertases
EC 3.4.21.-
Proprotein Convertase 9
EC 3.4.21.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
375-382Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.
Références
Timmis A, Townsend N, Gale CP, et al. European society of cardiology: cardiovascular disease statistics 2019. Eur Heart J. 2020;41:12–85.
doi: 10.1093/eurheartj/ehz859
pubmed: 31820000
Wilkins E, Wilson L, Wickramasinghe K, et al. European cardiovascular disease statistics 2017. Brussels: European Heart Network; 2017.
Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52.
doi: 10.1016/S0140-6736(04)17018-9
pubmed: 15364185
Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham heart study and the epidemiology of cardiovascular diseases: a historical perspective. Lancet. 2014;383:999–1008.
doi: 10.1016/S0140-6736(13)61752-3
pubmed: 24084292
Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459–72.
doi: 10.1093/eurheartj/ehx144
pubmed: 28444290
pmcid: 5837225
Koskinas K, Wilhelm M, Windecker S. Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance. Swiss Med Wkly. 2016;146:w14333.
pubmed: 27400448
Wang Y, Liu Z‑P. PCSK9 inhibitors: novel therapeutic strategies for lowering LDLcholesterol. Mini Rev Med Chem. 2019;19:165–76.
doi: 10.2174/1389557518666180423111442
pubmed: 29692249
Directorate-General for Health and Food Safety [Internet]. Uitvoeringsbesluit Van De Commissie tot verlening van een vergunning krachtens Verordening (EG) nr. 726/2004 van het Europees Parlement en de Raad voor het in de handel brengen van “Repatha—evolocumab”, een geneesmiddel voor menselijk gebruik. Register of Commission Documents. 2015. [cited 2021 Oct 27]. Available from: https://ec.europa.eu/transparency/documents-register/detail?ref=C (2015)5159&lang=de.
Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A. 2003;100(3):928–33.
doi: 10.1073/pnas.0335507100
pubmed: 12552133
pmcid: 298703
Lambert G, Sjouke B, Choque B, Kastelein JJP, Hovingh GK. The PCSK9 decade. J Lipid Res. 2012;53:2515–24.
doi: 10.1194/jlr.R026658
pubmed: 22811413
pmcid: 3494258
Dachverband der Sozialversicherungsträger. Erstattungskodex – EKO. Vienna: Samson Druck; 2022. pp. 419–21.
Vogler S, Haasis MA, Dedet G, Lam J, Bak Pedersen H. Medicines reimbursement policies in Europe. WHO—Regional Office for Europe; 2018.
Pappas A. PCSK9 inhibitors’ battle for reimbursement: Germany’s decision and implications in other countries. Health advances blog. 2018 April 10. https://healthadvancesblog.com/2018/04/10/pcsk9-inhibitors-battle-for-reimbursement-germanys-decision-and-implications-in-other-countries . Accessed 8 Sept 2022.
Diabetologie-Online. LDL-C-Senkung – Alirocumab ab sofort in Deutschland wieder verfügbar. http://www.diabetologie-online.de/a/senkung-des-ldl-cholesterins-alirocumab-ab-sofort-in-deutschland-wieder-verfuegbar-2303273 (Created 4 Apr 2021). Accessed 8 Sept 2022.
Ministerie van Volksgezondheid W en S. GVS assessment of evolocumab (Repatha®) for the treatment of primary hypercholesterolaemia—Report—National Health Care Institute. Ministerie van Volksgezondheid, Welzijn en Sport. 2019. https://english.zorginstituutnederland.nl/publications/reports/2019/01/23/evolocumab-repatha-for-the-treatment-of-primary-hypercholesterolaemia ;. Accessed 8 Sept 2022.
Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370:1809–19.
doi: 10.1056/NEJMoa1316222
pubmed: 24678979
Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators, Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500–9.
doi: 10.1056/NEJMoa1500858
Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489–1489.
doi: 10.1056/NEJMoa1501031
pubmed: 25773378
Keech AC, Oyama K, Sever PS, et al. Efficacy and safety of long-term evolocumab use among asian subjects—a subgroup analysis of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial. Circ J. 2021;85:2063–70.
doi: 10.1253/circj.CJ-20-1051
pubmed: 33980763
Piccinni C, Antonazzo IC, Maggioni AP, et al. PCSK9 inhibitors’ new users: analysis of prescription patterns and patients’ characteristics from an Italian real-world study. Clin Drug Investig. 2020;40:173–81.
doi: 10.1007/s40261-019-00877-3
pubmed: 31797311
Kosmas CE, Silverio D, Ovalle J, Montan PD, Guzman E. Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia. Patient Prefer Adherence. 2018;12:2263–6.
doi: 10.2147/PPA.S149423
pubmed: 30464416
pmcid: 6214408
Gragnano F, Concilio C, Cesaro A, et al. Adherence to PCSK9 inhibitors in high cardiovascular risk patients in real-world setting: results from a single-center experience and comparison with statin therapy. Eur Heart J. 2017;38:314.
doi: 10.1093/eurheartj/ehx502.P1513
Raebel MA, Schmittdiel J, Karter AJ, Konieczny JL, Steiner JF. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care. 2013;51(8 Suppl 3):11–21.
doi: 10.1097/MLR.0b013e31829b1d2a
Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25:2303–10.
doi: 10.1185/03007990903126833
pubmed: 19635045
Timmis A, Vardas P, Townsend N, et al. European society of cardiology: cardiovascular disease statistics 2021. Eur Heart J. 2022;43:716–99.
doi: 10.1093/eurheartj/ehab892
pubmed: 35016208
World Health Organization. Cardiovascular diseases (CVDs). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases- (cvds). (Created 11 June 2021). Accessed 19 July 2022.
Manteuffel M, Williams S, Chen W, Verbrugge RR, Pittman DG, Steinkellner A. Influence of patient sex and gender on medication use, adherence, and prescribing alignment with guidelines. J Womens Health. 2014;23:112–9.
doi: 10.1089/jwh.2012.3972
Granger BB, Ekman I, Granger CB, et al. Adherence to medication according to sex and age in the CHARM programme. Eur J Heart Fail. 2009;11:1092–8.
doi: 10.1093/eurjhf/hfp142
pubmed: 19875409
Kim SJ, Kwon OD, Han EB, et al. Impact of number of medications and age on adherence to antihypertensive medications: a nationwide population-based study. Medicine. 2019;98(49):e17825.
doi: 10.1097/MD.0000000000017825
pubmed: 31804305
pmcid: 6919523
Leening MJG, Ferket BS, Steyerberg EW, et al. Sex differences in lifetime risk and first manifestation of cardiovascular disease: prospective population based cohort study. BMJ. 2014;349:g5992.
doi: 10.1136/bmj.g5992
pubmed: 25403476
pmcid: 4233917
Sulzgruber P, Sinkovec H, Kazem N, et al. Adherence to high-intensity statin therapy after acute coronary syndrome and its impact on patient outcome. Eur Heart J. 2020;41:3345.
Marcum ZA, Huang H‑C, Romanelli RJ. Statin dosing instructions, medication adherence, and low-density lipoprotein cholesterol: a cohort study of incident statin users. J Gen Intern Med. 2019;34:2559–66.
doi: 10.1007/s11606-019-05180-7
pubmed: 31367867
pmcid: 6848741
Perreault S, Blais L, Lamarre D, et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol. 2005;59:564–73.
doi: 10.1111/j.1365-2125.2005.02355.x
pubmed: 15842555
pmcid: 1884848
Vonbank A, Agewall S, Kjeldsen KP, et al. Comprehensive efforts to increase adherence to statin therapy. Eur Heart J. 2017;38:2473–9.
pubmed: 28077470
Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep. 2013;15:291.
doi: 10.1007/s11883-012-0291-7
pubmed: 23225173
pmcid: 3534845
Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44:1410–21.
doi: 10.1345/aph.1P150
pubmed: 20702755
pmcid: 3641194
Lemstra M, Blackburn D, Crawley A, Fung R. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol. 2012;28:574–80.
doi: 10.1016/j.cjca.2012.05.007
pubmed: 22884278
Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs—do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1995;332:1125–31.
doi: 10.1056/NEJM199504273321703
pubmed: 7700285
Zafrir B, Egbaria A, Stein N, Elis A, Saliba W. PCSK9 inhibition in clinical practice: treatment patterns and attainment of lipid goals in a large health maintenance organization. J Clin Lipidol. 2021;15:202–11.
doi: 10.1016/j.jacl.2020.11.004
pubmed: 33243717
Hines DM, Rane P, Patel J, Harrison DJ, Wade RL. Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors. Vasc Health Risk Manag. 2018;14:409–18.
doi: 10.2147/VHRM.S180496
pubmed: 30573963
pmcid: 6292243
Dachverband der Sozialversicherungsträger. PCSK9-Hemmer-Zentren. https://www.sozialversicherung.at/cdscontent/?contentid=10007.844501&portal=svportal (Created 30 June 2022). Accessed 25 July 2022.